Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863702 | 0.98 | DPP4 (0.47) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL2869525 | 0.98 | DPP4 (0.47) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL2447602 | 0.98 | DPP4 (0.47) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL2453079 | 0.98 | DPP4 (0.47) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL2448263 | 0.98 | DPP4 (0.47) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL5562923 | 0.98 | DPP4 (0.51) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL24679533 | 0.96 | DPP4 (0.45) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL5573676 | 0.96 | DPP4 (0.45) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL2449974 | 0.93 | DPP4 (0.54) | DPP4CYP1A2CA1CA2CA4 | |
| SCHEMBL18802306 | 0.91 | DPP4 (0.57) | DPP4CYP1A2CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| CN-1898317-B | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-1867540-B | Amides, polyolefin resin compositions, and moldings | NEW JAPAN CHEM CO LTD | 2010-05-26 | — | — | CN | disclosed |
| US-7723413-B2 | Method and composition for control of crystallization rate of polyolefin resin, resin composition and resin molding | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7696380-B2 | Such as 1,2,3-propanetricarboxylic acid tris(trans-2-methylcycloheylamide; nucleation | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| EP-1715000-B1 | METHOD AND COMPOSITION FOR CONTROL OF CRYSTALLIZATION RATE OF POLYOLEFIN RESIN, RESIN COMPOSITION AND RESIN MOLDING | NEW JAPAN CHEM CO LTD (JP) | 2010-03-10 | — | — | EP | disclosed |
| EP-2083045-A1 | Method and composition for control of crystallization rate of polyolefin resin, resin composition and resin molding | New Japan Chemical Co., Ltd. (JP) | 2009-07-29 | — | — | EP | disclosed |
| CN-100467468-C | Triaza-spiropiperidine derivatives for use as GLYT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1678177-B1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070142514-A1 | Method and composition for control of crystallization rate of polyolefin resin, resin composition and resin molding | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1678177-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| EP-1674447-A1 | AMIDES, POLYOLEFIN RESIN COMPOSITIONS, AND MOLDINGS | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-20050245607-A1 | N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides | SYNGENTA CROP PROTECTION, INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1534664-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | Syngenta Participations AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20040214721-A1 | Novel n-bisaryl- and n-aryl-cycloalkylidenyl-alpha-sulfin- and alpha-sulfonamino acid amides | SYNGENTA CROP PROTECTION, INC. | 2004-10-28 | — | — | US | disclosed |
| EP-1399418-A1 | NOVEL N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-$G(a)-SULFIN- AND $G(a)-SULFONAMINO ACID AMIDES | Syngenta Participations AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004011417-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003002525-A1 | NOVEL N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-$G(a)-SULFIN- AND $G(a)-SULFONAMINO ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214721-A1 | Novel n-bisaryl- and n-aryl-cycloalkylidenyl-alpha-sulfin- and alpha-sulfonamino acid amides | ARSA, SFN, HCCS | DPP4 2478/4885CYP1A2 2229/4885CA1 224/4885 |
| US-20050245607-A1 | N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides | CBR3, CBR1, AKR1C3 | DPP4 3428/4885CYP1A2 286/4885CA1 765/4885 |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | DPP4 554/4885CYP1A2 2564/4885CA1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.